These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38804813)

  • 1. A plain language summary of the perspectives of women who were interviewed about their experiences with uterine fibroids.
    Hunsche E; Rakov V; Scippa K; Witherspoon B; McKain L
    J Comp Eff Res; 2024 Aug; 13(8):e230195. PubMed ID: 38804813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    J Comp Eff Res; 2024 Aug; 13(8):e230194. PubMed ID: 38934918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A; Lukes AS; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    J Comp Eff Res; 2023 Aug; 12(8):e230069. PubMed ID: 37477173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
    Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
    Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HO; Li Y; McKain L; Arjona Ferreira JC; Langenberg AG; Wagman RB; Stewart EA
    Pain Manag; 2023 Apr; 13(4):205-211. PubMed ID: 37183454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
    Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
    Woodhead N; Pounds R; Irani S; Pradhan P
    J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
    Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
    F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing burden, risk factors, and perceived impact of uterine fibroids on women's lives in rural Haiti: implications for advancing a health equity agenda, a mixed methods study.
    Millien C; Manzi A; Katz AM; Gilbert H; Smith Fawzi MC; Farmer PE; Mukherjee J
    Int J Equity Health; 2021 Jan; 20(1):1. PubMed ID: 33386078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women.
    Zimmermann A; Bernuit D; Gerlinger C; Schaefers M; Geppert K
    BMC Womens Health; 2012 Mar; 12():6. PubMed ID: 22448610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing research in symptomatic uterine fibroids with development of a computable phenotype for use with electronic health records.
    Hoffman SR; Vines AI; Halladay JR; Pfaff E; Schiff L; Westreich D; Sundaresan A; Johnson LS; Nicholson WK
    Am J Obstet Gynecol; 2018 Jun; 218(6):610.e1-610.e7. PubMed ID: 29432754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the Bleeding and Pelvic Discomfort Scale for Use in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
    Hudgens S; Gauthier M; Hunsche E; Kang J; Li Y; Scippa K; As-Sanie S
    Value Health; 2022 Dec; 25(12):1986-1994. PubMed ID: 35863945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.